Equities

Cipla Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Cipla Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)--
  • Today's Change--
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Cipla Limited is an India-based global pharmaceutical company. The Company is engaged in manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The Company operates through two segments: Pharmaceuticals and New ventures. The Pharmaceuticals segment is engaged in developing, manufacturing, selling, and distributing generic or branded generic medicines, as well as Active Pharmaceutical Ingredients (API). The New ventures segment includes the operations of the Company, a consumer healthcare, Biosimilars and specialty business. Its product portfolio spans complex generics, as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective and central nervous system (CNS). Its geographical segments include India, the United States, South Africa, and the Rest of the World. It has its network of manufacturing, trading and other incidental operations in India and International markets.

  • Revenue in USD (TTM)256.45m
  • Net income in USD45.23m
  • Incorporated1935
  • Employees30.31k
  • Location
    Cipla LtdMumbai CentralMUMBAI 400013IndiaIND
  • Phone+91 2 224826000
  • Fax+91 2 224826120
  • Websitehttps://www.cipla.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
CIPLA:NSI since
announced
Transaction
value
Inzpera Healthsciences LtdDeal completed03 Nov 202503 Nov 2025Deal completed-10.10%12.47m
Pulse Pharmaceuticals Pvt Ltd-Doloneuron & Zolsoma BrandDeal completed20 May 202520 May 2025Deal completed-9.46%--
Data delayed at least 15 minutes, as of Feb 11 2026 10:12 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Rhythm Pharmaceuticals Inc174.33m-197.71m6.87bn283.00--46.10--39.38-3.10-3.102.744.430.40061.036.66616,021.20-44.19-52.46-57.53-61.2289.40---110.32-354.184.53-27.830.2693--68.06---43.26------
Krystal Biotech Inc373.16m198.91m7.85bn275.0040.626.9038.3921.046.666.6612.5039.260.33580.76163.291,356,960.0017.90-4.8119.49-5.0794.26--53.30-41.519.73--0.00--473.02--715.58---7.91--
Axsome Therapeutics Inc561.26m-229.53m9.29bn683.00--125.76--16.55-4.67-4.6711.401.470.91212.403.50821,761.40-37.30-59.62-68.09-80.3291.86---40.89-134.061.50-28.270.7255--42.53---20.05--75.71--
Halozyme Therapeutics, Inc.1.24bn595.49m9.43bn350.0016.8718.7113.937.594.764.769.904.290.57281.213.933,551,006.0027.4522.2035.1025.7084.5580.8547.9145.391.37--0.74990.0022.4438.9557.71--21.50--
Jazz Pharmaceuticals PLC4.16bn-368.48m10.06bn2.80k--2.5431.672.42-6.07-6.0767.8165.180.35220.9365.591,484,940.00-3.121.36-3.621.5088.4988.18-8.853.981.442.170.57520.006.1213.4835.021.37-23.40--
Avidity Biosciences Inc20.87m-549.79m11.28bn391.00--5.67--540.49-4.17-4.170.158912.850.0111--2.7853,370.84-29.13-30.46-31.29-33.14-----2,634.59-1,901.74----0.00--13.9936.27-51.87--97.52--
Biomarin Pharmaceutical Inc3.09bn520.42m11.46bn3.04k22.361.8919.003.702.672.6715.8231.530.42780.45123.951,017,764.007.202.188.042.4681.3276.4316.826.073.10--0.08970.0017.9710.86154.62---9.83--
Cipla Ltd (ADR)256.45m45.23m11.95bn30.31k----232.8946.590.04010.0401--0.5721------43,216.78--------47.90--17.64--1.2957.900.1115--19.29--33.56------
Elanco Animal Health Inc4.59bn36.00m12.72bn9.00k357.581.8918.022.770.07160.07169.2313.580.34221.245.30510,111.100.2683-2.710.2993-3.0254.9654.720.7841-9.521.231.300.3735--0.49817.65127.4637.85-3.99--
Neurocrine Biosciences Inc2.68bn428.00m13.72bn1.80k32.874.5729.995.124.194.1926.2530.130.68780.76114.441,490,389.0010.9710.4112.7112.7198.3798.4715.9515.713.27--0.00--24.8124.4836.6855.9420.97--
BridgeBio Pharma Inc353.78m-797.12m13.97bn725.00------39.48-4.19-4.191.86-10.030.4254----487,972.40-96.88-75.74-125.35-94.2495.7896.67-227.74-716.923.76-2.893.52--2,285.2740.4816.70--11.63--
Moderna Inc2.23bn-3.12bn16.41bn5.80k--1.76--7.35-8.05-8.055.7623.860.15982.191.71384,827.60-22.3113.72-25.9118.7663.4976.34-139.6123.743.73--0.00610.00-52.75121.8624.46--101.61--
Data as of --. Currency figures normalised to Cipla Ltd's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.